Demodex Blepharitis

A long time ago, in a galaxy far, far away, DED diagnosis and treatment was a spartan affair undertaken by a tiny cadre of Jedi doctors who were pitied by their doctor brothers and sisters if they, and their quest, were acknowledged at all.

WAILEA, Hawaii — In this video from Hawaiian Eye 2021, Cathleen M. McCabe, MD, discusses data revealing the impact Demodex blepharitis has on patients’ quality of life.

The results of the Atlas study, presented at the virtual Association for Research in Vision and Ophthalmology meeting, show the functional and psychosocial impact Demodex blepharitis has on patients, according to a Tarsus press release.

Demodex folliculorum and Demodex brevis are ectoparasites of phylum Arthropoda that inhabit the skin of humans.

The FDA acceptance of an investigational new drug application and an article diving into Demodex led recent cornea/external disease news on Healio/OSN.

A look at Demodex blepharitis and an FDA approval led ophthalmology news in the first week of April.

The Demodex mite, of which there are at least 65 species, is the most common microscopic ectoparasite found on human skin. Demodex folliculorum is responsible for Demodex blepharitis, which accounts for at least 45% of blepharitis cases.

Tarsus Pharmaceuticals and LianBio have entered into a strategic partnership to develop and market TP-03 for the treatment of meibomian gland dysfunction and Demodex blepharitis in Greater China, according to a press release.

In honor of the popular horror movie Dawn of the Dead, I thought it would be appropriate to discuss the newest frontline treatment to combat Demodex mites, which attack the ocular surface and potentially damage our premium IOL outcomes.

Wow! 2020 sure did not turn out quite the way we expected, did it? 2020, the year of the eye doctor. So not.